Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

Not Applicable

Completed

• Conditions: LDL - Low Density Lipoprotein Receptor Disorder; Rosuvastatin
• Interventions: Drug: Rosuvastatin

• Registration Number: NCT06910098
• Lead Sponsor: Central Park Medical College

Brief Summary

Particpants were divided into groups based on doses of rosuvastatin and were assessed and for CPK, LDL and AST levels

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-01
• Primary Completion: 2024-06-30
• Study Completion: 2024-08-31
• Status Verified: 2025-03
• Study First Submitted: 2025-03-22
• Study First Submitted QC: 2025-03-27
• Last Update Submitted: 2025-03-27
• Study First Posted: 2025-04-04
• Last Update Posted: 2025-04-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 195

Inclusion Criteria

patients who were already on statins

Exclusion Criteria

hereditary diseases including familial hypercholesterolemia and kidney diseases

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 1	Rosuvastatin	receiving drug dose of 5mg
Group 2	Rosuvastatin	receiving grug dose of 10 mg
Group 3	Rosuvastatin	receiving dose of 20 mg

Primary Outcome Measures

Name	Time	Method
impact of rosuvstatin over LDL, CPK and AST levels	12 weeks	Pre- and post-intervention levels of Aspartate Aminotransferase (AST) in U/L were recorded and were compared in all study groups for assessment of the impact of various doses of rosuvastatin in terms of liver damage.

Trial Locations

Locations (1)

Central Park Teaching Hospital; 🇵🇰 Lahore, Pakistan